Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
Community Health (CYH) Divests Hospital for $92 Million
by Zacks Equity Research
Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Here's What is Driving Amgen (AMGN) Stock's Outperformance
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.
3 Reasons Growth Investors Will Love Horizon Therapeutics (HZNP)
by Zacks Equity Research
Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Horizon Therapeutics (HZNP) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
by Zacks Equity Research
Alkermes shares have surged in the past six months, owing to strong sales performance of its new drug Lybalvi and its decision to separate the oncology unit.
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Horizon's (HZNP) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) reports better-than-expected fourth-quarter 2022 results as it beats the Zacks Consensus Estimate for both revenues and earnings.
Horizon Therapeutics (HZNP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Horizon Therapeutics (HZNP) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.01% and 1.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
by Sanghamitra Saha
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSEW
Incyte (INCY) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Horizon (HZNP) Dazodalibep Meets Goal in Sjogren's Syndrome Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces that a phase II Sjogren's syndrome study of its candidate, dazodalibep, meets the primary endpoint for the second population.
HZNP vs. RGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HZNP vs. RGEN: Which Stock Is the Better Value Option?